Cogstate Ltd (ASX: CGS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cogstate Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$164.11 million
P/E Ratio
22.85
Dividend Yield
0.00%
Shares Outstanding
172.59 million
Earnings per share
0.032
Dividend per share
N/A
Year To Date Return
-34.95%
Earnings Yield
4.38%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cogstate Ltd (ASX: CGS)
Latest News
Healthcare Shares
The Cogstate share price is rocketing again, up another 27% on Thursday
Share Gainers
Why Cogstate, Mayne Pharma, Race Oncology, and Whitehaven Coal are charging higher
Healthcare Shares
Why is the CogState share price rocketing 61% higher today?
Technology Shares
Top broker says this ASX tech share has over 30% upside
Earnings Results
3 ASX All Ordinaries shares being sold off following FY22 results
Healthcare Shares
CogState (ASX:CGS) share price crashes 20% on quarterly update
Healthcare Shares
CogState (ASX:CGS) share price rockets 9% on record quarter
Broker Notes
2 small cap ASX shares with exciting growth potential: experts
Share Market News
Here's why the Cogstate (ASX:CGS) share price is up 5% today
Share Gainers
Why the Cogstate (ASX:CGS) share price is surging 23% today
Healthcare Shares
Here's why the Actinogen Medical (ASX: ACW) share price is up 20%
Ask a Fund Manager
4 ASX shares to gain exposure to international market growth: fund manager
Frequently Asked Questions
-
No, Cogstate does not pay dividends at this stage.
-
Cogstate Ltd listed on the ASX on 13 February 2004.
CGS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cogstate Ltd
Cogstate Ltd (ASX: CGS) is a neuroscience technology company specialising in brain health assessments. The principal activity of the company is the sale of technology and services to measure cognition.
The company provides licensed digital tests for health professionals and medical researchers. Its services include scientific consultancy, project management, data management, statistical analysis, and reporting. Cogstate generates the bulk of its revenue from its clinical trials segment.
Cogstate's technology has been used in more than 2,000 scientific and clinical trial studies. These include fields such as Alzheimer's, depression, and bipolar disorder research as well as studies investigating cognitive impairment in athletes as a result of concussive injuries.
CGS Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Nov 2024 | $0.97 | $-0.01 | -1.03% | 34,854 | $0.98 | $0.98 | $0.97 |
| 12 Nov 2024 | $0.98 | $0.01 | 1.04% | 41,911 | $0.97 | $0.98 | $0.97 |
| 11 Nov 2024 | $0.97 | $0.00 | 0.00% | 47,642 | $0.97 | $1.00 | $0.97 |
| 08 Nov 2024 | $0.97 | $-0.01 | -1.03% | 31,376 | $0.97 | $0.97 | $0.97 |
| 07 Nov 2024 | $0.97 | $0.00 | 0.00% | 27,389 | $0.97 | $0.97 | $0.97 |
| 06 Nov 2024 | $0.97 | $-0.01 | -1.03% | 146,337 | $0.98 | $0.98 | $0.97 |
| 05 Nov 2024 | $0.98 | $0.00 | 0.00% | 68,358 | $0.98 | $0.99 | $0.97 |
| 04 Nov 2024 | $0.98 | $0.00 | 0.00% | 63,308 | $0.98 | $0.98 | $0.97 |
| 01 Nov 2024 | $0.98 | $-0.01 | -1.02% | 119,399 | $0.97 | $0.98 | $0.97 |
| 31 Oct 2024 | $0.98 | $-0.02 | -2.00% | 108,871 | $0.97 | $1.00 | $0.97 |
| 30 Oct 2024 | $1.00 | $0.00 | 0.00% | 244,229 | $1.00 | $1.04 | $0.97 |
| 29 Oct 2024 | $1.00 | $0.05 | 5.26% | 68,715 | $0.96 | $1.00 | $0.96 |
| 28 Oct 2024 | $0.95 | $-0.03 | -3.08% | 136,274 | $0.97 | $0.98 | $0.94 |
| 25 Oct 2024 | $0.98 | $0.02 | 2.08% | 41,581 | $0.93 | $0.98 | $0.93 |
| 24 Oct 2024 | $0.96 | $-0.01 | -1.04% | 151,259 | $0.97 | $0.97 | $0.92 |
| 23 Oct 2024 | $0.97 | $0.02 | 2.12% | 448,920 | $0.95 | $1.00 | $0.94 |
| 22 Oct 2024 | $0.95 | $0.02 | 2.17% | 23,953 | $0.92 | $0.95 | $0.92 |
| 21 Oct 2024 | $0.92 | $0.01 | 1.10% | 77,061 | $0.92 | $0.93 | $0.88 |
| 18 Oct 2024 | $0.91 | $0.01 | 1.11% | 38,085 | $0.90 | $0.91 | $0.89 |
| 17 Oct 2024 | $0.90 | $-0.02 | -2.19% | 23,978 | $0.90 | $0.90 | $0.88 |
| 16 Oct 2024 | $0.92 | $0.02 | 2.23% | 90,488 | $0.90 | $0.92 | $0.86 |
| 15 Oct 2024 | $0.90 | $-0.01 | -1.11% | 71,539 | $0.90 | $0.90 | $0.89 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 06 Nov 2024 | Bradley O'Connor | Issued | 920,251 | $920,251 |
Issue of securities. Performance Rights: 920,251
|
| 10 Sep 2024 | Bradley O'Connor | Exercise | 1,000,000 | $340,000 |
Exercise of options.
|
| 10 Sep 2024 | Bradley O'Connor | Issued | 1,000,000 | $340,000 |
Exercise of options.
|
| 23 Aug 2024 | Martyn Myer | Buy | 100,000 | $108,051 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Martyn Kenneth Myer | Non-Executive ChairmanNon-Executive Director | Oct 1999 |
Mr Myer is Chair of the Doherty Institute at the University of Melbourne and the board of the Australian Chamber Orchestra. He is also a member of the Risk and Compliance Committee.
|
| Mr Bradley O'Connor | Chief Executive OfficerManaging Director | Nov 2005 |
Mr O'Connor has responsibility for overall strategic direction and day-to-day operations as well as development of expansion opportunities outside of the core clinical trials business. Prior to that, Mr O'Connor held senior positions at Spherion Group, Australian Wine Exchange and PricewaterhouseCoopers.
|
| Ms Ingrid Anne Player | Non-Executive Director | Aug 2019 |
Ms Player has considerable international commercial and regulatory experience that spans different markets and industries, which she gained in private legal practice in Australia and in The Netherlands. She has held senior executive roles with Healthscope Ltd, a private healthcare provider in Australia, including the former positions of Group Executive Legal, Governance and Sustainability, and General Counsel and Company Secretary from 2005 until 2019. She is Chair of Risk and Compliance Committee.
|
| Mr Richard van den Broek | Non-Executive Director | Aug 2010 |
Mr van den Broek is founder and managing partner of HSMR Advisors LLC, a U.S. based fund manager with an investment emphasis on small and mid-cap biotech public companies. Prior to his time as an investor in the healthcare industry Mr van den Broek had a ten-year career as a biotech analyst, starting at Oppenheimer & Co., then Merrill Lynch, and finally at Hambrecht & Quist.
|
| Dr Richard Mohs | Non-Executive Director | Jan 2017 |
Dr Mohs is currently Chief Scientific Officer for the Global Alzheimer's Platform (GAP) Foundation, a non- profit devoted to developing the speed and quality of Alzheimer's disease research. Richard also serves as a consultant to academic institutions, foundations, and biopharmaceutical companies, and is a member of the Board of Governors for the Alzheimer's Drug Discovery Foundation. He is also a member of the Risk and Compliance Committee.
|
| Ms Kim Wenn | Non-Executive Director | Nov 2020 |
Ms Wenn brings technology experience and commercial expertise to the Board of Cogstate, with over 30 years of experience in innovation roles. Kim's experience includes, among other things, business strategy, governance and change management with a focus on digital disruption. He is also a member of the Risk and Compliance Committee.
|
| Mr David James Franks | Company Secretary | Feb 2021 |
-
|
| Ms Kristi Geddes | Joint Company Secretary | Apr 2023 |
-
|
| Darren Watson | Chief Financial Officer |
-
|
|
| Pam Ventola | Chief Science Officer |
-
|
|
| David James Franks | Company Secretary |
-
|
|
| Rachel Colite | Executive Vice President Clinical Trials |
-
|
|
| Kristi Geddes | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Dagmar Dolby Fund | 25,732,802 | 15.10% |
| Citicorp Nominees Pty Limited | 25,414,142 | 14.90% |
| National Nominees Limited | 20,556,374 | 12.00% |
| Myer & Myer Pty Ltd | 14,424,569 | 8.40% |
| HSBC Custody Nominees | 12,717,797 | 7.40% |
| Anacacia Pty Limited | 10,976,129 | 6.40% |
| J P Morgan Nominees Australia Pty Limited | 9,550,619 | 5.60% |
| Mpyer Investments Pty Ltd | 6,061,872 | 3.50% |
| Mr Bradley John O'Connor | 3,488,429 | 2.00% |
| BNP Paribas Nominees Pty Ltd | 2,633,372 | 1.50% |
| Myer & Myer Pty Ltd i | 2,313,000 | 1.40% |
| BNP Paribas Nominees Pty Ltd i | 2,020,262 | 1.20% |
| Mr Alistair David Strong | 1,320,000 | 0.80% |
| Beta Gamma Pty Ltd | 1,220,000 | 0.80% |
| Anacacia Pty Ltd | 1,216,210 | 0.70% |
| Mutual Trust Pty Ltd | 1,129,806 | 0.70% |
| Mr David Alexander Simpson and Mrs Dawn Gentry Simpson | 1,000,689 | 0.70% |
| BNP Paribas Noms Pty Ltd | 985,588 | 0.60% |
| Ronnocob Pty Ltd | 917,173 | 0.50% |
| HSBC Custody Nominees i | 892,182 | 0.50% |
